Company news
Fangzhou Inc. news in 2026
Fangzhou Inc.'s news releases, calls and decks from 2026, newest first.
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 October 2026
November 2, 2026
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2026
October 5, 2026
Adoption of share incentive scheme
September 27, 2026
Fangzhou Releases 2026 Interim Report, Deepening "AI + Chronic Care" as a Lifetime Health Service Partner
September 25, 2026
2026 Interim Report
September 24, 2026
Fangzhou Reports Sustained Revenue and Profit Growth as AI-Powered Chronic Care Strategy Gains Momentum
August 27, 2026
Fangzhou Launches Novo Nordisk’s Once-Weekly Basal Insulin/GLP-1 Therapy in China
July 19, 2026
Fangzhou Inc. Appoints Healthcare Industry Veteran Wang Haijiao as Chief Executive Officer Following a Year of Record Growth and Profitability
March 26, 2026
Fangzhou Reports Robust 2025 Financial Results, Boosted by AI Chronic Care Strategy
March 19, 2026
Fangzhou and Youcare Pharmaceutical Group Form Strategic Alliance to Advance AI-Driven Chronic Care Services
February 28, 2026
Fangzhou’s MaaS Platform Recognized as Industry Leader at Guangdong Digital Economy Conference
February 10, 2026
Fangzhou ’XingShi’ Large Language Model Highlighted Among China’s Most Anticipated Healthcare Models for 2026
February 9, 2026
Fangzhou Wins Tencent Health ‘AI-Powered Future Award’ as MaaS Platform Drives AI Chronic Care
February 8, 2026
Fangzhou Issues Positive Profit Forecast as AI-Driven Chronic Care Model Delivers First Full-Year Profit
January 26, 2026
Fangzhou Raises HK$150 Million in Share Placement to Accelerate AI-Powered Chronic Care Platform
January 26, 2026